Gilead Sciences reported quarterly earnings that missed analysts' expectations on Thursday as sales of its hepatitis C drugs came in below estimates.
The pharmaceutical company posted earnings of $3.03 a share ex-items on $7.79 billion in revenue. Analysts expected Gilead to report earnings of about $3.15 a share on $8.12 billion in revenue, according to a consensus estimate from Thomson Reuters.
The company also reiterated its full-year guidance and announced that it is raising its dividend by 9.3 percent to 47 cents a share.
Gilead shares were down about 6 percent after hours.